Moreover, high SULT1A1 provides selective vulnerability to anticancer compounds RITA, AF, and ONC-1 and lay out a rationale for a new combination therapy to overcome TMX resistance in young breast cancer patients. Here, SULT1A1 is linked to breast carcinoma.